|
1 Indications And Usage Herzuma Is A Her2/neu Receptor Antagonist Indicated For: The Treatment Of Her2-Overexpressing Breast Cancer. ( 1.1 , 1.2 ) The Treatment Of Her2-Overexpressing Metastatic Gastric Or Gastroesophageal Junction Adenocarcinoma. ( 1.3 ) Select Patients For Therapy Based On An Fda-Approved Companion Diagnostic For A Trastuzumab Product. ( 1 , 2.1 ) 1.1 Adjuvant Breast Cancer Herzuma Is Indicated For Adjuvant Treatment Of Her2 Overexpressing Node Positive Or Node Negative (Er/pr Negative Or With One High Risk Feature [See Clinical Studies (14.1) ] ) Breast Cancer As Part Of A Treatment Regimen Consisting Of Doxorubicin, Cyclophosphamide, And Either Paclitaxel Or Docetaxel As Part Of A Treatment Regimen With Docetaxel And Carboplatin As A Single Agent Following Multi-Modality Anthracycline Based Therapy. Select Patients For Therapy Based On An Fda-Approved Companion Diagnostic For A Trastuzumab Product [See Dosage And Administration (2.1) ] . 1.2 Metastatic Breast Cancer Herzuma Is Indicated: In Combination With Paclitaxel For First-Line Treatment Of Her2-Overexpressing Metastatic Breast Cancer As A Single Agent For Treatment Of Her2-Overexpressing Breast Cancer In Patients Who Have Received One Or More Chemotherapy Regimens For Metastatic Disease. Select Patients For Therapy Based On An Fda-Approved Companion Diagnostic For A Trastuzumab Product [See Dosage And Administration (2.1) ] . 1.3 Metastatic Gastric Cancer Herzuma Is Indicated, In Combination With Cisplatin And Capecitabine Or 5-Fluorouracil, For The Treatment Of Patients With Her2 Overexpressing Metastatic Gastric Or Gastroesophageal Junction Adenocarcinoma Who Have Not Received Prior Treatment For Metastatic Disease. Select Patients For Therapy Based On An Fda-Approved Companion Diagnostic For A Trastuzumab Product [See Dosage And Administration (2.1) ] .
|